Why the study?
Do EGFR inhibitors prevent Angiotensin II-induced cardiac hypertrophy in preclinical models?
Do EGFR inhibitors prevent Angiotensin II-induced cardiac hypertrophy in preclinical models?
Inhibition of EGFR attenuates Angiotensin II-induced cardiac hypertrophy and remodeling, highlighting a potential therapeutic strategy for Ang II-associated cardiac diseases.
No takes yet. Share an insight, caveat, or question.
EGFR inhibition merits testing in cardiac disease models; hypothesis-generating in animals, clinical translation remains open.
Peng et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: